134 related articles for article (PubMed ID: 38687605)
1. Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.
Sirenko M; Bernard E; Creignou M; Domenico D; Farina A; Arango Ossa JE; Kosmider O; Hasserjian RP; Jädersten M; Germing U; Sanz GF; van de Loosdrecht AA; Gurnari C; Follo MY; Thol FR; Zamora L; Pinheiro RF; Pellagatti A; Elias HK; Haase DT; Sander B; Orna E; Zoldan K; Eder LN; Sperr WR; Thalhammer R; Ganster C; Adès L; Tobiasson M; Palomo L; Della Porta MG; Huberman KH; Fenaux P; Belickova M; Savona MR; Klimek V; Santos FPS; Boultwood J; Kotsianidis I; Santini V; Sole F; Platzbecker U; Heuser M; Valent P; Finelli C; Voso MT; Shih LY; Ogawa S; Fontenay M; Jansen JH; Cervera J; Ebert BL; Bejar R; Greenberg PL; Gattermann N; Malcovati L; Cazzola M; Beck DB; Hellstrom-Lindberg ES; Papaemmanuil E
Blood; 2024 Apr; ():. PubMed ID: 38687605
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort.
Gurnari C; Pascale MR; Vitale A; Diral E; Tomelleri A; Galossi E; Falconi G; Bruno A; Crisafulli F; Frassi M; Cattaneo C; Bertoli D; Bernardi M; Condorelli A; Morsia E; Poloni A; Crisà E; Caravelli D; Triggianese P; Brussino L; Battipaglia G; Bindoli S; Sfriso P; Caroni F; Dragani M; Mallegni F; Pilo F; Firinu D; Curti A; Papayannidis C; Olivieri A; Kordasti S; Albano F; Pane F; Musto P; Bocchia M; Lugli E; Breccia M; Frigeni M; Dagna L; Greco R; Franceschini F; Campochiaro C; Cantarini L; Voso MT
Am J Hematol; 2024 Feb; 99(2):254-262. PubMed ID: 38108611
[TBL] [Abstract][Full Text] [Related]
3. Clinical and genetic features of Japanese cases of MDS associated with VEXAS syndrome.
Kunimoto H; Miura A; Maeda A; Tsuchida N; Uchiyama Y; Kunishita Y; Nakajima Y; Takase-Minegishi K; Yoshimi R; Miyazaki T; Hagihara M; Yamazaki E; Kirino Y; Matsumoto N; Nakajima H
Int J Hematol; 2023 Oct; 118(4):494-502. PubMed ID: 37062784
[TBL] [Abstract][Full Text] [Related]
4. VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder.
Huang H; Zhang W; Cai W; Liu J; Wang H; Qin T; Xu Z; Li B; Qu S; Pan L; Huang G; Gale RP; Xiao Z
Exp Hematol Oncol; 2021 Mar; 10(1):23. PubMed ID: 33741056
[TBL] [Abstract][Full Text] [Related]
5. Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population.
Beck DB; Bodian DL; Shah V; Mirshahi UL; Kim J; Ding Y; Magaziner SJ; Strande NT; Cantor A; Haley JS; Cook A; Hill W; Schwartz AL; Grayson PC; Ferrada MA; Kastner DL; Carey DJ; Stewart DR
JAMA; 2023 Jan; 329(4):318-324. PubMed ID: 36692560
[TBL] [Abstract][Full Text] [Related]
6. Accurate stratification between VEXAS syndrome and differential diagnoses by deep learning analysis of peripheral blood smears.
Chabrun F; Lacombe V; Dieu X; Geneviève F; Urbanski G
Clin Chem Lab Med; 2023 Jun; 61(7):1275-1279. PubMed ID: 36722042
[TBL] [Abstract][Full Text] [Related]
7. Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome.
Kataoka A; Mizumoto C; Kanda J; Iwasaki M; Sakurada M; Oka T; Fujimoto M; Yamamoto Y; Yamashita K; Nannya Y; Ogawa S; Takaori-Kondo A
Int J Hematol; 2023 Jun; 117(6):919-924. PubMed ID: 36641501
[TBL] [Abstract][Full Text] [Related]
8. Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients.
Georgin-Lavialle S; Terrier B; Guedon AF; Heiblig M; Comont T; Lazaro E; Lacombe V; Terriou L; Ardois S; Bouaziz JD; Mathian A; Le Guenno G; Aouba A; Outh R; Meyer A; Roux-Sauvat M; Ebbo M; Zhao LP; Bigot A; Jamilloux Y; Guillotin V; Flamarion E; Henneton P; Vial G; Jachiet V; Rossignol J; Vinzio S; Weitten T; Vinit J; Deligny C; Humbert S; Samson M; Magy-Bertrand N; Moulinet T; Bourguiba R; Hanslik T; Bachmeyer C; Sebert M; Kostine M; Bienvenu B; Biscay P; Liozon E; Sailler L; Chasset F; Audemard-Verger A; Duroyon E; Sarrabay G; Borlot F; Dieval C; Cluzeau T; Marianetti P; Lobbes H; Boursier G; Gerfaud-Valentin M; Jeannel J; Servettaz A; Audia S; Larue M; Henriot B; Faucher B; Graveleau J; de Sainte Marie B; Galland J; Bouillet L; Arnaud C; Ades L; Carrat F; Hirsch P; Fenaux P; Fain O; Sujobert P; Kosmider O; Mekinian A; ;
Br J Dermatol; 2022 Mar; 186(3):564-574. PubMed ID: 34632574
[TBL] [Abstract][Full Text] [Related]
9. Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS.
Ferrada MA; Sikora KA; Luo Y; Wells KV; Patel B; Groarke EM; Ospina Cardona D; Rominger E; Hoffmann P; Le MT; Deng Z; Quinn KA; Rose E; Tsai WL; Wigerblad G; Goodspeed W; Jones A; Wilson L; Schnappauf O; Laird RS; Kim J; Allen C; Sirajuddin A; Chen M; Gadina M; Calvo KR; Kaplan MJ; Colbert RA; Aksentijevich I; Young NS; Savic S; Kastner DL; Ombrello AK; Beck DB; Grayson PC
Arthritis Rheumatol; 2021 Oct; 73(10):1886-1895. PubMed ID: 33779074
[TBL] [Abstract][Full Text] [Related]
10. USAID Associated with Myeloid Neoplasm and VEXAS Syndrome: Two Differential Diagnoses of Suspected Adult Onset Still's Disease in Elderly Patients.
Delplanque M; Aouba A; Hirsch P; Fenaux P; Graveleau J; Malard F; Roos-Weil D; Belfeki N; Drevon L; Oganesyan A; Groh M; Mahévas M; Razanamahery J; Maigne G; Décamp M; Miranda S; Quemeneur T; Rossignol J; Sailler L; Sébert M; Terriou L; Sevoyan A; Hakobyan Y; Georgin-Lavialle S; Mekinian A
J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884286
[TBL] [Abstract][Full Text] [Related]
11. Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies.
Sakuma M; Blombery P; Meggendorfer M; Haferlach C; Lindauer M; Martens UM; Kern W; Haferlach T; Walter W
Leukemia; 2023 May; 37(5):1080-1091. PubMed ID: 36823397
[TBL] [Abstract][Full Text] [Related]
12. Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.
Janusz K; Izquierdo MM; Cadenas FL; Ramos F; Sánchez JMH; Lumbreras E; Robledo C; Del Real JS; Caballero JC; Collado R; Bernal T; Pedro C; Insunza A; de Paz R; Xicoy B; Salido E; García JS; Mínguez SS; García CM; Muñoz AMS; Barba MS; Rivas JMH; Abáigar M; Campelo MD
Ann Hematol; 2021 Aug; 100(8):1995-2004. PubMed ID: 33409621
[TBL] [Abstract][Full Text] [Related]
13. Looking beyond VEXAS: Coexistence of undifferentiated systemic autoinflammatory disease and myelodysplastic syndrome.
Oganesyan A; Hakobyan Y; Terrier B; Georgin-Lavialle S; Mekinian A
Semin Hematol; 2021 Oct; 58(4):247-253. PubMed ID: 34802547
[TBL] [Abstract][Full Text] [Related]
14. Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1.
Obiorah IE; Patel BA; Groarke EM; Wang W; Trick M; Ombrello AK; Ferrada MA; Wu Z; Gutierrez-Rodrigues F; Lotter J; Wilson L; Hoffmann P; Cardona DO; Patel N; Dulau-Florea A; Kastner DL; Grayson PC; Beck DB; Young NS; Calvo KR
Blood Adv; 2021 Aug; 5(16):3203-3215. PubMed ID: 34427584
[TBL] [Abstract][Full Text] [Related]
15. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
[TBL] [Abstract][Full Text] [Related]
16. Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases.
Jachiet V; Ricard L; Hirsch P; Malard F; Pascal L; Beyne-Rauzy O; Peterlin P; Maria ATJ; Vey N; D'Aveni M; Gourin MP; Dimicoli-Salazar S; Banos A; Wickenhauser S; Terriou L; De Renzis B; Durot E; Natarajan-Ame S; Vekhoff A; Voillat L; Park S; Vinit J; Dieval C; Dellal A; Grobost V; Willems L; Rossignol J; Solary E; Kosmider O; Dulphy N; Zhao LP; Adès L; Fenaux P; Fain O; Mohty M; Gaugler B; Mekinian A;
Clin Exp Med; 2023 Jul; 23(3):803-813. PubMed ID: 35953763
[TBL] [Abstract][Full Text] [Related]
17. Spectrum of clonal hematopoiesis in VEXAS syndrome.
Gutierrez-Rodrigues F; Kusne Y; Fernandez J; Lasho T; Shalhoub R; Ma X; Alessi H; Finke C; Koster MJ; Mangaonkar A; Warrington KJ; Begna K; Xie Z; Ombrello AK; Viswanatha D; Ferrada M; Wilson L; Go R; Kourelis T; Reichard K; Olteanu H; Darden I; Hironaka D; Alemu L; Kajigaya S; Rosenzweig S; Calado RT; Groarke EM; Kastner DL; Calvo KR; Wu CO; Grayson PC; Young NS; Beck DB; Patel BA; Patnaik MM
Blood; 2023 Jul; 142(3):244-259. PubMed ID: 37084382
[TBL] [Abstract][Full Text] [Related]
18. [Clinical and genetic features of MDS associated with VEXAS syndrome].
Kunimoto H
Rinsho Ketsueki; 2024; 65(4):255-264. PubMed ID: 38684436
[TBL] [Abstract][Full Text] [Related]
19. Case Report: Coexistence of Multiple Myeloma and Auricular Chondritis in VEXAS Syndrome.
Matsumoto H; Fujita Y; Fukatsu M; Ikezoe T; Yokose K; Asano T; Tsuchida N; Maeda A; Yoshida S; Hashimoto H; Temmoku J; Matsuoka N; Yashiro-Furuya M; Sato S; Murakami M; Sato H; Sakuma C; Kawashima K; Shakespear N; Uchiyama Y; Watanabe H; Kirino Y; Matsumoto N; Migita K
Front Immunol; 2022; 13():897722. PubMed ID: 35757758
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of ASXL1 gene variant in patients with myelodysplastic syndrome].
Chen M; Liu J; Chao H; Qin W; Jiang N; Lu X; Cen L; Jiang Y; Cai X; Zhang R; Wang Q
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2020 Feb; 37(2):110-115. PubMed ID: 32034733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
